AUG 27, 2019 Business

Machavert Pharmaceuticals Signs Exclusive License Agreement to Control RAL GTPase Inhibitors against KRAS Cancers

Machavert obtains worldwide exclusive license to small molecule RAL GTPase inhibitors to treat…

MAR 28, 2019 Science

Machavert Pharmaceuticals Will Present at the Annual Meeting of the American Association of Cancer Research (AACR)

A poster presentation reporting Natural Killer cell activation against cancer by a phospholipid…

FEB 13, 2019 People

CEOCFO magazine interview with Machavert Pharmaceuticals CEO, Dr. Jakub Staszak-Jirkovsky

The interview focused on core technologies currently developed at Machavert and their possible…

JAN 9, 2019 Business

Machavert Pharmaceuticals to Present at Biotech Showcase™, 2019 in San Francisco

Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on immuno-oncology…

NOV 26, 2018 Science

Machavert Pharmaceuticals Unveils a New Bioactive Lipid Drug Candidate for Cancer Treatment

A poster presentation reporting anti-proliferation activity for MP1000 in human KRAS mutant…

NOV 19, 2018 Business

Colorado Advanced Industries Awards Machavert $250K to Develop a Novel Therapeutics Against KRAS Cancers

Grant award to advance RAL GTPase inhibitors in KRAS mutant solid tumors models with Machavert’s…

NOV 15, 2018 Science

Science Advisory Board review meeting took place on November 2

We have shared our latest R&D progress with our Science Advisory (SAB) review panel that…

AUG 31, 2018 Business

Machavert closes A round financing of $4.5m

Machavert has closed their A Round of financing of ~$4.5m by raising $2.2 million in the second…

JUL 31, 2018 Business

Machavert’s Annual General Meeting

Machavert’s Shareholders Annual General Meeting took place on June 27th in Prague, Czech…

Page 1 of 3123